Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2017-11-30 Declaration of Voting R…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement in Swedish regarding a change in the total number of shares and votes following a directed new share issue ('riktad nyemission'). The key phrases are 'Ändring av antal aktier och röster' (Change in number of shares and votes) and the specific mention of the increase due to a share issue. This directly relates to changes in the company's capital structure or share count. Comparing this to the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category, as it covers announcements regarding new share issues. The document length is short (2010 chars), but it is reporting the *result* of a capital change, not just announcing that a report is available, making SHA more specific than RPA or RNS.
2017-11-30 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-September 2017. It contains detailed financial statements, management commentary, business updates, and project portfolio analysis. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2017
2017-11-21 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim report January - September 2017' and contains detailed financial information, including net revenues, loss before tax, and loss per share for both the third quarter and the first nine months of 2017. It also includes a CEO commentary, business operations overview, and project updates. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2017
2017-11-21 English
NeuroVives kliniska utvecklingsprojekt KL1333 får positivt utlåtande om europeisk Orphan Drug Designation
Regulatory Filings Classification · 1% confidence The document is a press release dated November 8, 2017, announcing that NeuroVive Pharmaceutical AB's development project KL1333 received a positive opinion for Orphan Drug Designation from the European Medicines Agency (EMA)'s Committee for Orphan Medicinal Products (COMP). The text details the implications of this designation (scientific advice, fee reductions, market exclusivity) and includes standard boilerplate information about the company, its pipeline, and its partner (Yungjin Pharm). This type of announcement, detailing a specific regulatory milestone or clinical update, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive announcement about a regulatory event (Orphan Drug Designation opinion) rather than a comprehensive financial report (10-K, IR) or a general market update (RNS), it fits best as an Earnings Release (ER) which often includes key operational and regulatory news, or potentially a Regulatory Filing (RNS) if it were less focused on operational progress. Given the focus on a major positive development milestone, ER is a strong candidate, but since it is not explicitly quarterly results, RNS (Regulatory Filings - general regulatory announcements) is the safest and most appropriate fallback for specific, non-financial regulatory news that doesn't fit other categories like DIRS, DIV, or CAP. However, in many databases, significant clinical/regulatory updates are often grouped with ERs or IRs. Since this is a specific, non-financial regulatory update, RNS is the most accurate fit based on the provided definitions, as it is a 'general regulatory announcement' that doesn't fit the other specific codes.
2017-11-08 Swedish
NeuroVive’s Clinical Development Project KL1333 Receives Positive Opinion on European Orphan Drug Designation
Regulatory Filings Classification · 1% confidence The document is an announcement dated November 8, 2017, regarding NeuroVive's clinical development project KL1333 receiving a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for Orphan Drug Designation. This is a specific, material event announcement concerning regulatory progress and potential future benefits (scientific advice, reduced fees, market exclusivity). It is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a transcript (CT). It is a specific regulatory/development update. Since it details a specific regulatory milestone (Orphan Drug Designation opinion) rather than just announcing the publication of a general report, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a specific, non-financial, material event disclosure required under regulations like the EU Market Abuse Regulation, which is explicitly mentioned at the end of the main body.
2017-11-08 English
NeuroVive Board Chair Resigns, New Chair Elected
Board/Management Information Classification · 1% confidence The document explicitly announces the resignation of the Board Chair (Gregory Batcheller) and the subsequent unanimous election of a new Chair (David Laskow-Pooley). This content directly relates to changes in the company's board of directors and senior management structure. This aligns perfectly with the definition for Board/Management Information (MANG). The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2017-11-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.